AR063497A1 - Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento - Google Patents
Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamentoInfo
- Publication number
- AR063497A1 AR063497A1 ARP070104628A ARP070104628A AR063497A1 AR 063497 A1 AR063497 A1 AR 063497A1 AR P070104628 A ARP070104628 A AR P070104628A AR P070104628 A ARP070104628 A AR P070104628A AR 063497 A1 AR063497 A1 AR 063497A1
- Authority
- AR
- Argentina
- Prior art keywords
- schizophrenia
- treatment
- prepare
- compound
- weight gain
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 abstract 6
- 201000000980 schizophrenia Diseases 0.000 abstract 4
- 208000021017 Weight Gain Diseases 0.000 abstract 3
- 230000004584 weight gain Effects 0.000 abstract 3
- 235000019786 weight gain Nutrition 0.000 abstract 3
- 208000007848 Alcoholism Diseases 0.000 abstract 2
- 208000028698 Cognitive impairment Diseases 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- 201000007930 alcohol dependence Diseases 0.000 abstract 2
- 229940121375 antifungal agent Drugs 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 230000005586 smoking cessation Effects 0.000 abstract 2
- 201000009032 substance abuse Diseases 0.000 abstract 2
- 231100000736 substance abuse Toxicity 0.000 abstract 2
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 230000008484 agonism Effects 0.000 abstract 1
- 230000000843 anti-fungal effect Effects 0.000 abstract 1
- 239000003429 antifungal agent Substances 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto de pirrodinil-2-ona de formulas: o una sal farmacéuticamente aceptable del mismo. Composiciones farmacéuticas que los comprenden. Su uso para preparar un medicamento util para el bloqueo de los receptores CB1 por medio de un mecanismo de agonismo inverso, en tratamiento de trastornos del comer asociados con ingesta excesiva de comida, obesidad, esquizofrenia, debilitamiento cognoscitivo asociado con esquizofrenia, abuso de sustancias o dependencia del alcohol, cesacion de fumar y tratamiento del aumento de peso inesperado observado durante el tratamiento con un antisicotico atípico, y en terapias de combinacion con un agente antimicotico, para tratamientos de trastornos seleccionados entre: aumento de peso, obesidad, esquizofrenia, debilitamiento cognoscitivo asociado con esquizofrenia, abuso de sustancias o dependencia del alcohol, cesacion de fumar y tratamiento del aumento de peso inesperados observado durante el tratamiento con un antimicotico atípico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86254006P | 2006-10-23 | 2006-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063497A1 true AR063497A1 (es) | 2009-01-28 |
Family
ID=39386481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104628A AR063497A1 (es) | 2006-10-23 | 2007-10-18 | Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8168659B2 (es) |
| EP (2) | EP2094684B1 (es) |
| JP (2) | JP5331002B2 (es) |
| KR (2) | KR101088236B1 (es) |
| CN (2) | CN101528732B (es) |
| AR (1) | AR063497A1 (es) |
| AT (1) | ATE492543T1 (es) |
| AU (1) | AU2007329808B2 (es) |
| BR (1) | BRPI0717347A2 (es) |
| CA (2) | CA2667210C (es) |
| CL (1) | CL2007003002A1 (es) |
| CY (1) | CY1111140T1 (es) |
| DE (1) | DE602007011495D1 (es) |
| DK (2) | DK2094684T3 (es) |
| EA (2) | EA015745B1 (es) |
| ES (2) | ES2398388T3 (es) |
| MX (2) | MX2009004053A (es) |
| PE (1) | PE20080926A1 (es) |
| PL (2) | PL2094684T3 (es) |
| PT (2) | PT2099784E (es) |
| SI (2) | SI2099784T1 (es) |
| TW (1) | TW200825067A (es) |
| WO (2) | WO2008070305A2 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20080926A1 (es) * | 2006-10-23 | 2008-07-19 | Lilly Co Eli | Compuestos cb1 |
| MX2010011547A (es) | 2008-04-22 | 2010-11-09 | Lilly Co Eli | Compuestos de 1,5-difenil-pirrolidin-2-ona como ligandos de cb-1. |
| AU2009238444B2 (en) * | 2008-04-22 | 2013-08-29 | Eli Lilly And Company | 1,5-diphenyl-pyrrolidin-2-one compounds as CB-1 ligands |
| WO2010057000A2 (en) * | 2008-11-13 | 2010-05-20 | The Trustees Of Columbia University In The City Of New York | Neuraminidase inhibitors and uses thereof |
| MX361778B (es) * | 2010-07-15 | 2018-12-17 | Oleg Iliich Epshtein | Composiciones farmaceuticas y metodos de tratamiento. |
| CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| WO2022132803A1 (en) * | 2020-12-14 | 2022-06-23 | The Board Of Trustees Of The Leland Stanford Junior University | Cb2 receptor agonists |
| WO2023205180A1 (en) | 2022-04-19 | 2023-10-26 | Nurix Therapeutics, Inc. | Biomarkers for cbl, and compositions and methods for their use |
| WO2023250097A1 (en) | 2022-06-22 | 2023-12-28 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds and antiemetic agents |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200533657A (en) * | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
| ES2315851T3 (es) * | 2004-02-19 | 2009-04-01 | Solvay Pharmaceuticals B.V. | Derivados de imidazolina que tienen actividad antagonista cb1. |
| US20060035245A1 (en) * | 2004-04-20 | 2006-02-16 | Ason Brandon L | Modulators of enzymatic nucleic acid elements mobilization |
| WO2007020502A2 (en) * | 2005-08-16 | 2007-02-22 | Pharmacia & Upjohn Company Llc | Cannabinoid receptor ligands and uses thereof |
| PE20080926A1 (es) * | 2006-10-23 | 2008-07-19 | Lilly Co Eli | Compuestos cb1 |
-
2007
- 2007-10-18 PE PE2007001418A patent/PE20080926A1/es not_active Application Discontinuation
- 2007-10-18 AR ARP070104628A patent/AR063497A1/es unknown
- 2007-10-18 TW TW096139051A patent/TW200825067A/zh unknown
- 2007-10-18 CL CL200703002A patent/CL2007003002A1/es unknown
- 2007-10-22 MX MX2009004053A patent/MX2009004053A/es active IP Right Grant
- 2007-10-22 ES ES07871196T patent/ES2398388T3/es active Active
- 2007-10-22 MX MX2009004054A patent/MX2009004054A/es active IP Right Grant
- 2007-10-22 US US12/441,570 patent/US8168659B2/en not_active Expired - Fee Related
- 2007-10-22 PL PL07871197T patent/PL2094684T3/pl unknown
- 2007-10-22 SI SI200731118T patent/SI2099784T1/sl unknown
- 2007-10-22 KR KR1020097008214A patent/KR101088236B1/ko not_active IP Right Cessation
- 2007-10-22 ES ES07871197T patent/ES2356025T3/es active Active
- 2007-10-22 EP EP07871197A patent/EP2094684B1/en not_active Not-in-force
- 2007-10-22 EP EP07871196A patent/EP2099784B1/en not_active Not-in-force
- 2007-10-22 WO PCT/US2007/082041 patent/WO2008070305A2/en active Application Filing
- 2007-10-22 PL PL07871196T patent/PL2099784T3/pl unknown
- 2007-10-22 US US12/444,692 patent/US7998985B2/en not_active Expired - Fee Related
- 2007-10-22 SI SI200730538T patent/SI2094684T1/sl unknown
- 2007-10-22 CN CN2007800394497A patent/CN101528732B/zh not_active Expired - Fee Related
- 2007-10-22 AT AT07871197T patent/ATE492543T1/de active
- 2007-10-22 CA CA2667210A patent/CA2667210C/en not_active Expired - Fee Related
- 2007-10-22 JP JP2009533586A patent/JP5331002B2/ja not_active Expired - Fee Related
- 2007-10-22 PT PT78711967T patent/PT2099784E/pt unknown
- 2007-10-22 BR BRPI0717347-4A2A patent/BRPI0717347A2/pt not_active IP Right Cessation
- 2007-10-22 CA CA2667372A patent/CA2667372C/en not_active Expired - Fee Related
- 2007-10-22 PT PT07871197T patent/PT2094684E/pt unknown
- 2007-10-22 CN CN2007800394514A patent/CN101528733B/zh not_active Expired - Fee Related
- 2007-10-22 DK DK07871197.5T patent/DK2094684T3/da active
- 2007-10-22 DK DK07871196.7T patent/DK2099784T3/da active
- 2007-10-22 JP JP2009533585A patent/JP5331001B2/ja not_active Expired - Fee Related
- 2007-10-22 AU AU2007329808A patent/AU2007329808B2/en not_active Ceased
- 2007-10-22 KR KR1020097008216A patent/KR101088229B1/ko not_active IP Right Cessation
- 2007-10-22 EA EA200970404A patent/EA015745B1/ru not_active IP Right Cessation
- 2007-10-22 WO PCT/US2007/082042 patent/WO2008070306A2/en active Application Filing
- 2007-10-22 DE DE602007011495T patent/DE602007011495D1/de active Active
- 2007-10-22 EA EA200970405A patent/EA015175B1/ru not_active IP Right Cessation
-
2011
- 2011-01-27 CY CY20111100093T patent/CY1111140T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063497A1 (es) | Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| CO2021000174A2 (es) | Composiciones tópicas para el alivio del dolor | |
| CO6331425A2 (es) | Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida | |
| JP2008523153A5 (es) | ||
| AR074632A1 (es) | Compuesto de amidofenoxiindazol, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util en el tratamiento de cancer | |
| UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| Tradtrantip et al. | Antidiarrheal efficacy and cellular mechanisms of a Thai herbal remedy | |
| AR077638A1 (es) | Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad | |
| AR124497A2 (es) | Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica | |
| BRPI0508540A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| DK1778680T3 (da) | Spirocykliske cyclohexaderivater | |
| WO2010015260A3 (en) | Administration by infusion for the treatment of ischemic effects | |
| PE20081799A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| DOP2012000269A (es) | Combinaciones que contienen 2, 3-dihidroimidazo[1,2-c]quinazolina sustituida | |
| AR065120A1 (es) | Compuesto de aril pirazol azoespirodecanona, su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende | |
| AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
| UY31403A1 (es) | "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos". | |
| MA33463B1 (fr) | Compositions à dose pharmaceutique solide fixe comprenant de l'irbésartan et de l'amlodipine, leur préparation et leur application thérapeutique | |
| BRPI0916282B8 (pt) | uso de um agonista do receptor-pgi2 no tratamento de insuficiência renal crônica | |
| CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
| BR112023000270A2 (pt) | Composto, composição farmacêutica, e, peptídeo | |
| EA200601901A1 (ru) | Композиции, содержащие иммуномодулирующие соединения для лечения и управления течением миелодиспластических синдромов и способы с их использованием | |
| CL2009001267A1 (es) | Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis. | |
| CL2019000753A1 (es) | Composición farmacéutica que comprende antagonista de receptor mineralocorticoide y su uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |